Although a higher TMB was observed in KRAS-mutated compared to wild-type PAAD, the TMB levels in PAAD rarely meet the ≥10 mutations/megabase threshold predictive of tumor inflammation and ICI response, suggesting the immunosuppressive effects of oncogenic KRAS signaling overpower the immune-stimulating features of increased TMB. The gene discussed is KRAS; the disease is neoplasm.